Suppr超能文献

一种用于评估炎症性肠病患者医疗保健使用情况和个人费用的新型自填式问卷的开发及重测信度:炎症性肠病资源使用问卷(IBD-RUQ)

Development and test-retest reliability of a new, self-report questionnaire assessing healthcare use and personal costs in people with inflammatory bowel disease: the Inflammatory Bowel Disease Resource Use Questionnaire (IBD-RUQ).

作者信息

Roukas Chris, Syred Jonathan, Gordeev Vladimir Sergeevich, Norton Christine, Hart Ailsa, Mihaylova Borislava

机构信息

Wolfson Institute of Population Health, Queen Mary University of London, London, UK.

Florence Nightingale Faculty of Nursing, Midwifery and Palliative Care, King's College London, London, UK.

出版信息

Frontline Gastroenterol. 2022 Jul 25;14(1):59-67. doi: 10.1136/flgastro-2022-102182. eCollection 2023.

Abstract

BACKGROUND AND AIMS

The increasing prevalence of inflammatory bowel disease (IBD) poses a substantial economic burden globally on health systems and societies. Validated instruments to collect data on healthcare and other service utilisation by patients with IBD are lacking. We developed a self-report patient questionnaire to capture key resource utilisation from health services, patient and societal perspectives.

METHODS

The IBD Resource Use Questionnaire (IBD-RUQ), developed by a multidisciplinary team, including patients, comprises 102 items across the six categories of outpatient visits, diagnostics, medication, hospitalisations, employment and out-of-pocket expenses over the past three months. The test-retest reliability of the IBD-RUQ was studied by administering it twice among patients with IBD with a 2-week time gap. The intraclass correlation coefficients and the average cost from the healthcare, societal and patient perspectives, between test and retest assessments, overall and by service category, were summarised.

RESULTS

The IBD-RUQ captures health service use, employment and out-of-pocket expenses. Of 55 patients who completed the first questionnaire, 48 completed the retest questionnaires and were included in the analyses. Test-retest reliability for categories of medications, diagnostics, specialist outpatient and inpatient services, and days off work due to IBD ranged from moderate to excellent; primary care visits showed more limited reliability. The annualised average self-reported health service, out-of-pocket and loss of productivity costs were £4844, £320 and £545 per patient, respectively.

CONCLUSIONS

The IBD-RUQ is a reliable and valid self-report measure of resource utilisation in adults with IBD and can be used to measure costs associated with IBD.

摘要

背景与目的

炎症性肠病(IBD)患病率的不断上升给全球卫生系统和社会带来了巨大的经济负担。目前缺乏用于收集IBD患者医疗保健及其他服务利用情况数据的有效工具。我们开发了一份患者自填问卷,从卫生服务、患者和社会角度获取关键资源利用情况。

方法

由包括患者在内的多学科团队开发的IBD资源利用问卷(IBD-RUQ)涵盖102个项目,分为门诊就诊、诊断检查、药物治疗、住院治疗、就业及过去三个月的自付费用这六个类别。通过在IBD患者中进行两次问卷调查,间隔两周,研究IBD-RUQ的重测信度。总结了重测评估之间总体及各服务类别的组内相关系数以及从医疗保健、社会和患者角度的平均成本。

结果

IBD-RUQ可获取卫生服务利用、就业及自付费用情况。在完成第一份问卷的55名患者中,48名完成了重测问卷并纳入分析。药物治疗、诊断检查、专科门诊和住院服务类别以及因IBD导致的误工天数的重测信度从中度到优秀不等;初级保健就诊的信度较为有限。每位患者每年自报的卫生服务、自付费用和生产力损失成本分别为4844英镑、320英镑和545英镑。

结论

IBD-RUQ是一种可靠且有效的IBD成年患者资源利用自报测量工具,可用于衡量与IBD相关的成本。

相似文献

2
The Impact of Inflammatory Bowel Disease in Canada 2018: Indirect Costs of IBD Care.
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S34-S41. doi: 10.1093/jcag/gwy050. Epub 2018 Nov 2.
3
The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S17-S33. doi: 10.1093/jcag/gwy055. Epub 2018 Nov 2.
4
Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study.
Lancet Gastroenterol Hepatol. 2020 May;5(5):454-464. doi: 10.1016/S2468-1253(20)30012-1. Epub 2020 Feb 13.
6
The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.
J Can Assoc Gastroenterol. 2019 Feb;2(Suppl 1):S49-S67. doi: 10.1093/jcag/gwy056. Epub 2018 Nov 2.
8
Knowledge in Inflammatory Bowel Disease: Translation to Portuguese, Validation, and Clinical Application of the IBD-KNOW Questionnaire.
GE Port J Gastroenterol. 2023 Jul 19;31(4):246-255. doi: 10.1159/000530628. eCollection 2024 Aug.
9
The Evolution of Health Care Utilisation and Costs for Inflammatory Bowel Disease Over Ten Years.
J Crohns Colitis. 2019 May 27;13(6):744-754. doi: 10.1093/ecco-jcc/jjz003.

引用本文的文献

本文引用的文献

1
Aspects and Challenges of Resource Use Measurement in Health Economics: Towards a Comprehensive Measurement Framework.
Pharmacoeconomics. 2021 Sep;39(9):983-993. doi: 10.1007/s40273-021-01048-z. Epub 2021 Jun 25.
2
Changing patterns in the epidemiology and outcomes of inflammatory bowel disease in the United Kingdom: 2000-2018.
Aliment Pharmacol Ther. 2020 May;51(10):922-934. doi: 10.1111/apt.15701. Epub 2020 Apr 1.
4
Disease status, patient quality of life and healthcare resource use for ulcerative colitis in the UK: an observational study.
Frontline Gastroenterol. 2014 Jul;5(3):183-189. doi: 10.1136/flgastro-2013-100409. Epub 2014 Jan 24.
5
Health-Related Quality of Life Impairment and Indirect Cost of Crohn's Disease: A Self-Report Study in Poland.
PLoS One. 2016 Dec 16;11(12):e0168586. doi: 10.1371/journal.pone.0168586. eCollection 2016.
6
Agreement found between self-reported and health insurance data on physician visits comparing different recall lengths.
J Clin Epidemiol. 2017 Feb;82:167-172. doi: 10.1016/j.jclinepi.2016.10.009. Epub 2016 Nov 5.
7
Understanding and Preventing the Global Increase of Inflammatory Bowel Disease.
Gastroenterology. 2017 Feb;152(2):313-321.e2. doi: 10.1053/j.gastro.2016.10.020. Epub 2016 Oct 25.
9
A Guideline of Selecting and Reporting Intraclass Correlation Coefficients for Reliability Research.
J Chiropr Med. 2016 Jun;15(2):155-63. doi: 10.1016/j.jcm.2016.02.012. Epub 2016 Mar 31.
10
Evolution of Costs of Inflammatory Bowel Disease over Two Years of Follow-Up.
PLoS One. 2016 Apr 21;11(4):e0142481. doi: 10.1371/journal.pone.0142481. eCollection 2016.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验